On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

JARDIANCE is not recommended in patients with type 1 diabetes mellitus. It may increase their risk of diabetic ketoacidosis. JARDIANCE is not recommended for use to improve glycemic control in ...

Diabetes is one of the most common chronic conditions worldwide, impacting millions of individuals. While it requires ...

Risk factors for DKA occurrence and recurrence in children with known diabetes are related to insulin omission, insulin pump failure, adolescent girls, poor metabolic control, psychosocial turmoil ...

FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again ...

Lexicon did manage to get approval for type 1 diabetes in Europe, but the product was never launched there for commercial ...

A 2023 article in Drug and Therapeutics Bulletin highlighted a case of a 17-year-old man who suffered from severe lactic ...

Medscape Medical News, October 27, 2024 Kidney Week 2024 Limited Kidney Benefits With Finerenone in Heart Failure An analysis ... hypertension, CKD, and DKA, said a study with up to 40 months ...

Lexicon Pharmaceuticals shares have been halted all day as a Food and Drug Administration advisory committee was scheduled to vote on Zynquista as an adjunct to insulin therapy for glycemic control in ...

Its physiological meaning has not yet been definitely determined, but the most common explanation is a failure of the body’s buffering mechanisms which leads to metabolic (lactic) acidosis ... Germany ...

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently ...

Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment ... Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms ...